TA1 10mg we yu de yuz

▎ TA1 Struktrɔ

Sos: PubChem

Sikyɔn: SDAAVDTSSEITTKDLKEKKEVVEEAEN Mɔlikul Fɔmula: C 129H 215N 33O55 Molikul Weyt: 3108.3 g/mol CAS Nɔmba: 62304-98-7 PubChem CID: 16130571. Di wan dɛn we de wok Sinonim dɛn: Taymalfasin;Zadaxin

▎ TA1 Risach

Wetin na TA1?

TA1 na polipεptida we kכmכp fכ 28 amino asid dεm. i nכmal fכ de insay di taymus εn i de ple imכtant rol insay di machכ εn difrεns prכsεs fכ di T sεl dεm.

Wetin na di risach bakgrɔn fɔ TA1?

TA1 na bayoaktiv polipεptida we dεn aylכt εn purify frכm taymosin frakshכn 5, we kכnsis fכ 28 amino asid dεm. di taymus na imכtant כgan na di imyun sistεm, we de mek difrεn tin dεm we de rεgεl di imyun fכ wok, εn taymosin na wan pan dεm. wit di dip stכdi fכ di wok we di taymus de du, pipul dεn dכn no sכmtεm se di aktif kכmכpכnt dεm we de insay am kin gεt pכtεnshal valyu fכ trit difrεn sik dεm.

Wetin na di mεkanism fכ akshכn fכ TA1?

Imyunmoduleshɔn: . 

TA1 na bayolojikal rispכns modifya we kin aktibכt difrεn sεl dεm na di imyun sistεm. i de mεnli rεgεl di imyun fכnshכn bay we i de εnhans di difrεns εn mεchurεshכn fכ di T sεl dεm (Sjogren MH, 2004; Mao L, 2023). spεshal wan, TA1 kin afekt taymosayt dεm bay we i de stimul dεn difrεns כ transfכm dεm to aktv T sεl dεm.

Di mɛkanism we de mek pɔsin nɔ gɛt inflammatory: 

We dɛn de trit COVID-19 nyumonia, TA1 de mek pɔsin wɛl frɔm nyumonia kwik kwik wan tru in anti-inflammatory mechanism. I kin ridyus di inflammatory rεspכns, protεkt di εliviεshכn כf COVID-19 nyumonia-rεlatεd simptom dεm lεk fiva εn taya, i kin mek i izi fכ abzכp εksudat, εn aksεlεrayt di rεkכvεshכn frכm COVID-19 nyumonia (Wang Z, 2023).

Aw Thymalfasin de mek di tכmכro sεl dεm apoptosis insay kεnsar tritmεnt?

εnhans di aktiviti fכ di imyun sεl dεm: 

thymalfasin na sεntetik taymopεptida we gεt hכy imyun-εnhans aktiviti. i kin εnhans di kil ifekt fכ di imyun sεl dεm pan di tכmכro sεl dεm, we de indaykt indyuz di apoptosis fכ di tכmכro sεl dεm. fכ egzampl, insay di tכmכro maykro envayroment, Thymalfasin kin promuot di difrεns εn machכ fכ di T sεl dεm εn εnhans di aktiviti fכ di T sεl dεm. as imכtant pat pan di imyun sistεm, di T sεl dεm kin no εn atak di tכmכro sεl dεm, we de mek di tכmכro sεl dεm apoptosis bay we dεn de rilis saytכtoksik sכbstans dεm εn כda we dεm.

Fɔ rigul di imyun rεspכns: 

as imyunopotensiator, Thymalfasin kin rεgεl di imyun rεspכns εn indyuz di apoptosis fכ di tכmכro sεl dεm. i kin εnhans di Th1 imyun rεspכns. Th1 sεl dεm mεnli de sekret saytokεn dεm lεk IFN-γ, we kin akt dayrekt pan tכmכro sεl dεm εn indyuz dεn apoptosis. apat frכm dat, Thymalfasin kin rεgεl di fכnshכn dεm fכ כda imyun sεl dεm bak, lεk fכ εnhans di aktiviti fכ di NK sεl dεm. NK sεl dεm kin kil di tכmכro sεl dεm dayrekt εn dεn kin indyuz di apoptosis fכ di tכmכro sεl dεm bay we dεn de sekret saytokεn dεm εn כda mεtכd dεm ^{[1] .}.

fכ impruv di imyun supεshכn we dεn de du anti-tכmכr tritmεnt: 

We dɛn de du di tritmɛnt fɔ di tumbu, bɔku tɛm di wan dɛn we sik kin gɛt imyunɔsupreshɔn, we go afɛkt di we aw di tumor tritmɛnt go wok fayn. thymalfasin kin impruv di imyun supεshכn we dεn jεnarεt we dεn de trit di anti-tכmכro, i kin εnhans di abiliti fכ di imyun sistεm fכ atak di tכmכro sεl dεm, εn so i kin mek di tכmכro sεl dεm apoptosis. Fɔ ɛgzampul, we dɛn de du kemotɛrapi ɔ rediotɛrapi, di pɔsin in imyun sistɛm go pwɛl te i rich sɔm mak. thymalfasin kin mek di imyun sεl dεm rεkכv εn proliferate, impruv di fכnshכn fכ di imyun sistεm, εn εnhans di kil ifekt pan di tכmכro sεl dεm.

thymosin alpha 1 gεt bכku bכku bayolojikal aktiviti dεm.

Sos:PubMed ^{[6] we dɛn pul am.}

Wetin na di aplikeshɔn dɛn fɔ Thymalfasin?

Vayral infεkshכn dεm: 

biכs fכ in immunomodulatory ifekt, dεn kin yuz TA1 bכku tεm fכ trit vayral infεkshכn dεm. Fɔ ɛgzampul, di tɛm we COVID-19 pandemik de, i dɔn sho gud klinik ɛfifikɛshɔn fɔ trit COVID-19 nyumonia. Risach sho se TA1 kin mek di kɔmɔn COVID-19 infɛkshɔn nɔ go bifo to siriɔs nyumonia tru difrɛn imyun-ɛnhans ɛn anti-inflammatory protɛkshɔn mɛkanism dɛn ^[2] . Speshal, fɔ di pasɛnt dɛn we dɛn trit wit TA1, di ɔspitul we dɛn bin de de bin shɔt bad bad wan, di prɔpɔshɔn fɔ rilif fɔ di simptom dɛn we gɛt fɔ du wit nyumonia (lɛk fiva ɛn taya) bin rili ay pas di wan we di kɔntrol grup bin gɛt, ɛn di eria fɔ inflammatory exudation we CT sho bin rili smɔl pas di wan we di kɔntrol grup bin gɛt ^[2] . Apat frɔm dat, multivariate Cox model analysis sho se di pasɛnt dɛn we yuz TA1 ɛn di yɔŋ pasɛnt dɛn bin gɛt signifyant fasta nɛgitiv kɔnvɔshɔn rit fɔ COVID-19 antijen dɛn ^[2] . Tα1 (di men kכmכpכnt fכ TA1) inkrεs di CD4+ T sεl kכnt pan pasεn dεm we gεt lכw-fכ כksijεn inhalεshכn sכpכt na beslayn fast pas standad tritmεnt, εn i kin ple rol fכ tritmεnt כspitul pasεnshכn wit haypoxemia εn limfopenia we kכz fכ COVID-19 ^[3]..

Tritmɛnt fɔ epataytis: 

TA1 gɛt sɔm ifɛkt bak pan di tritmɛnt fɔ epataytis. Dɛn kin yuz am as monotɛrapi fɔ epataytis B ɔ dɛn kin yuz am wit intafɛron α-2b fɔ trit epataytis C. Spɛshal wan, wan stɔdi dɔn sho se we dɛn de trit epataytis B, dɛn bin ebul fɔ no di ɛfifikɛshɔn fɔ TA1 insay 4 klinik trayal dɛn we involv 195 pasɛnt dɛn. Insay wan pan di stɔdi dɛm, 9 pan 17 pasɛnt dɛm we dɛn trit wit TA1 bin gɛt ɛpatitis B vayrɔs (HBV) DNA kliarens na siks mɔnt, kɔmpia wit 10 pan 16 pasɛnt dɛm we dɛn trit wit intafɛron α-2b ɛn 4 pan 15 pasɛnt dɛm na di histrikal kɔntrol grup.

Adjuvant tritmɛnt: Dɛn kin yuz TA1 bak bɔku bɔku wan fɔ trit kansa. Fכ pasεnshכn dεm we gεt rεsεktabl nכn-smכl sεl lכng kεnsar (NSCLC) εn liva kεnsar, insay adjuvant tritmεnt, TA1 kin sכmtεm impruv di כvala sכvayv rεt (OS) (Mao L, 2023). Fɔ di pasɛnt dɛn we gɛt lokal advans NSCLC we nɔ kin rɛsɛkt, TA1 kin rili ridyus limfopenia ɛn nyumonia we dɛn kin kɔz bay rediotɛrapi ɛn kimotɛrapi, ɛn wan tren de fɔ mek OS bɛtɛ ^[4]..

Fɔ mek di anti-tumor imyuniti bɛtɛ: 

prεklinik εvidεns sho se TA1 kin rivεs di M2 polarizeshכn we di efferocytosis fכ makrofag dεm indyuz bay we i de aktibכt di TLR7/SHIP1 aks, εnhans di efikכs fכ kεnsar kεmothεrapi, εn εnhans di anti-tכmכr imuniti bay we i de transfכm 'kol tכmכro' to 'hכt tכmכro' (Mao L, 2023). apat frכm dat, TA1 gεt prכtektiv ifekt bak fכ ridyus kolεt we di imyun chεkpכynt inhibito dεm (ICI) kכz εn i kin εnhans di klinik efεktiv fכ ICI dεm ^[4] . Tα1 as adjuvant tritmεnt afta liva kεnsar rεsεkshכn kin impruv di prכgnosis fכ pasεnshכn dεm wit sכm hεpatosεlyul kכrεkshכn. Insay wan retrospektiv kɔhɔt stɔdi, dɛn sheb di pasɛnt dɛn we gɛt smɔl ɛpatosɛlular kansa we dɛn du liva rɛsekshɔn to tu grup, grup A (rɛsekshɔn + Tα1) ɛn grup B (rɛsekshɔn nɔmɔ). Afta wan midyan fכlכ-ap fכ 47.0 mכnt, di 1-, 3-, εn 5-ia כvala sכvayv rεt εn rεkכrεshכn-fri sכvayv rεt fכ pasεnshכn na grup A bin hכy pas di wan dεm na grup B. Multivariate analisis sho se Tα1 na indipεndεnt prכgnostik fכktכ fכ כvala sכvayv rεt εn rεkכrεshכn-fri sכvayv rεt ^[5]..

Fɔ mek di imyun wok bak ɛn fɔ mek di vaksin bɛtɛ: 

TA1 kin yuz fכ trit imyunokomprכmis stet dεm εn malignεns dεm εn as εnhansεr fכ vaksin rεspכns dεm ^{[4, 6]} . i kin rεgεl di imyun sistεm εn εnhans di T sεl fכ wok, εn i kin gεt klinik bεnεfit fכ sik dεm we di imyun fכnshכn we de wok fayn כ we nכ de wok fayn lεk akyu εn krכnik infεkshכn, kεnsar, εn vaksin nכn-rεspכns ^[4] . Stɔdi dɔn pruv se insay siriɔs sɛpsis, dɛn dɔn sho se TA1 kin mek di imyun wok bak ɛn ɛp fɔ ridyus di rit we di sik pipul dɛn kin day ^[4]..

Fɔ mek dɛn nɔ gɛt COVID-19 infɛkshɔn ɛn kɔmplikeshɔn dɛn we de pan pasɛnt dɛn we de du rɛnɛral dayalaysis: 

Dɛn kin tek di pasɛnt dɛn we gɛt ɛnd-stej rɛnɛral sik (ESRD) we de gɛt ɛmodayalis (HD) as dɛn kin rili sɔfa fɔ gɛt SARS-CoV2 infɛkshɔn bikɔs ɔf tin dɛn lɛk ol ej, kɔmɔrɔbiditi lod, yuz drɔgs, ɛn di nid fɔ go na dayalaysis klinik dɛn bɔku tɛm. Fɔs stɔdi dɔn sho se TA1, as adjuvant to di influenza vaysin, kin ɛp fɔ mek di antibodi rispɔns we di ol pipul dɛn (inklud di HD pasɛnt dɛn) gɛt to di influenza vaysin ɛn ridyus di influenza infɛkshɔn. Insay di fɔs tɛm we di COVID-19 pandemik bin de, di wan dɛn we de du risach bin de tɔk se if dɛn gi TA1 to pipul dɛn we gɛt HD, dat go mek di wan dɛn we gɛt COVID-19 nɔ bɔku ɛn di bad we aw dɛn kin gɛt am. As of Julay 1, 2022, 254 ESRD/HD pasɛnt dɛn frɔm fayv dayalaysis sɛnta dɛn na Kansas Siti, Misɔri bin inklud insay di stɔdi, pan dɛn 194 pasɛnt dɛn bin randomly divayd insay grup A (subcutaneous injection of 1.6mg TA1 tu tɛm insay di wik fɔ 8 wik) ɛn grup B (kɔntrol grup, we nɔ gɛt TA1) ^[7].

fכ kכnklud, as polipεptida wit yunik imyunomodulatory fכnshכn dεm, TA1 dכn sho pכtεnshal aplikεshכn in plεnti aspεkt dεm na di mεdikal fil. We dɛn de trit vayral infɛkshɔn, i kin gɛt bɔku ifɛkt pan sik dɛn lɛk epataytis B ɛn COVID-19. I nɔ kin jɔs mek di sik nɔ kam kwik kwik wan ɛn ridyus di inflamɛns bɔt i kin mek di sik nɔ go bifo ɛn i kin mek di sik pipul dɛn wɛl. we i kam pan di tכmכro tritmεnt, i kin indyuz di apoptosis fכ di tכmכro sεl dεm tru mכltipכl path dεm, εnhans di kil ifekt fכ di imyun sεl dεm pan di tכmכro sεl dεm, εn impruv di imyun supεsiv stet, we de sho pכsitiv pכrfomans fכ trit difrεn kεnsar dεm lεk lכng kεnsar εn liva kεnsar.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Wang Z na risachman wit difrɛn akademik bakgrɔn ɛn bɔku kɔlabɔraytiv ɛkspiriɛns akɔdin to bɔku institiushɔn dɛn. Dɛn risach intɛres de span intadisiplinari fil dɛm lɛk Ɛnjinia, Spɛktroskɔpi, Kwɛstyɔn, Dɛntis, Ɔral Sɔjri & Mɛdisin, ɛn Fiziks. Wang Z dɔn gɛt fɔ du wit big big ɔganayzeshɔn ɛn yunivasiti dɛn, lɛk di Yunivasiti ɔf Chaynish Akademi fɔ Sayns (CAS), Yunnan Yunivasiti, Pekin Yunivasiti, Hunan Agrikalchɔral Yunivasiti, Shanghai Jiao Tong Yunivasiti, ɛn bɔku ɔda wan dɛn. Dɛn wok de sho se dɛn de pe atɛnshɔn mɔ pan inovashɔn ɛn wok togɛda, mɔ pan eria dɛn we gɛt fɔ du wit layt industrial optoɛlektronik injinɛri, mɛdikal aplikeshɔn, ɛn advans matirial sayɛns. Tru patnaship wit institiushɔn dɛn lɛk di Jiangsu Prɔvinshal Risach Sɛnta fɔ Layt Indastrial Ɔptoilɛktronik Ɛnjinia & Tɛknɔlɔji ɛn di Eya Fos Militari Mɛdikal Yunivasiti, Wang Z dɔn kɔntribyut to ɔl tu di tiori advansmɛnt ɛn prɛktikal aplikeshɔn dɛn na dɛn fild dɛn we dɛn sabi. Wang Z de list in di rεfrεns כf saytεshכn [2].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Sjogren M H. Thymalfasin: na imyun sistεm εnhans fכ di tritmεnt fכ di liva sik.[J]. J ɔ rnal ov Gastroεntr ɔ l ɔ ji ɛn Ɛpat ɔ l ɔ ji, 2004,19 Suppl 6: S69-S72. DOI: 10.1111/j.1440-1746.2004.03635.x. Di wan dɛn we de wok fɔ di kɔmni

[2] Wang Z, Wang C, Fei X, ɛn ɔda pipul dɛn. Thymalfasin tεrapi de aksεlεrayt COVID-19 nyumonia rihabiliteshכn tru anti-inflammatory mεkanism dεm[J]. Nyumonia, 2023, 15 (1).DOI: 10.1186/s41479-023-00116-6.

[3] Shehadeh F, Bɛnitez G, Maylɔna E. K., ɛn ɔda pipul dɛn. Wan Paylɔt Trayal fɔ Thymalfasin (Thymosin-α-1) fɔ Trit Ɔspitul Peshɛnt dɛn wit Haypoksɛmia ɛn Limfosaytopenia Bikɔs ɔf Koronavayrɔs Sik 2019 Infɛkshɔn[J]. J ɔ rnal ov Inf ɛ ksh ɔ n Disiz, 2023,227(2):226-235.DOI:10.1093/infdis/jiac362.

[4] Mao L. Thymosin alpha 1-Rimajin in brכda aplikεshכn dεm na di imyuno-כnkכlכji εra[J]. Int ɛ rnash ɔ nal Imyunofarmak ɔ l ɔ ji, 2023,117.DOI: 10.1016/j.intimp.2023.109952.

[5] Hɛ C, Pɛng W, Li C, ɛn ɔda pipul dɛn. Thymalfasin, wan prɔmis adjuvant tεrapi in sכm hεpatosεlyulכr kכrεkshכn afta liva rεsεkshכn[J]. Mεdisin, 2017,96(16).DOI:10.1097/MD.0000000000006606.

[6] Dominari A, Hathaway Iii D, Pandav K, ɛn ɔda pipul dɛn. Thymosin alpha 1: Wan komprehensiv rivyu fכ di litεrachכ.[J]. Wol J ɔ rnal ɔ f Vayr ɔ l ɔ ji, 2020,9(5):67-78.DOI:10.5501/wjv.v9.i5.67.

[7] Tuthill C. W., Awad A., Parrigon M, ɛn ɔda pipul dɛn. Wan payɔl trayal fɔ Thymalfasin (Ta1) fɔ mek dɛn nɔ gɛt covid-19 infɛkshɔn ɛn sik dɛn we dɛn kin gɛt pan rɛnɛral dayalaysis pasɛnt dɛn: Prɛliminari ripɔt[J]. Int ɛ rnash ɔ nal Imyunofarmak ɔ l ɔ ji, 2023,117.DOI: 10.1016/j.intimp.2023.109950.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.